308 related articles for article (PubMed ID: 24882384)
21. Clinical outcomes and prognostic factors of patients with advanced mesothelioma treated in a phase I clinical trials unit.
Papadatos-Pastos D; Roda D; De Miguel Luken MJ; Petruckevitch A; Jalil A; Capelan M; Michalarea V; Lima J; Diamantis N; Bhosle J; Molife LR; Banerji U; de Bono JS; Popat S; O'Brien MER; Yap TA
Eur J Cancer; 2017 Apr; 75():56-62. PubMed ID: 28214659
[TBL] [Abstract][Full Text] [Related]
22. Metabolic response assessment with 18F-FDG-PET/CT is superior to modified RECIST for the evaluation of response to platinum-based doublet chemotherapy in malignant pleural mesothelioma.
Kanemura S; Kuribayashi K; Funaguchi N; Shibata E; Mikami K; Doi H; Kitajima K; Hasegawa S; Nakano T
Eur J Radiol; 2017 Jan; 86():92-98. PubMed ID: 28027772
[TBL] [Abstract][Full Text] [Related]
23. [Prognosis related clinical and molecular factors in malignant pleural mesothelioma].
Wang YY; Zhang H; Bai H; Wang SH; Wu MN; An TT; Zhao J; Zhuo ML; Duan JC; Wang ZJ; Wang J
Zhonghua Jie He He Hu Xi Za Zhi; 2013 Mar; 36(3):162-8. PubMed ID: 23856136
[TBL] [Abstract][Full Text] [Related]
24. A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma.
Nowak AK; Cook AM; McDonnell AM; Millward MJ; Creaney J; Francis RJ; Hasani A; Segal A; Musk AW; Turlach BA; McCoy MJ; Robinson BW; Lake RA
Ann Oncol; 2015 Dec; 26(12):2483-90. PubMed ID: 26386124
[TBL] [Abstract][Full Text] [Related]
25. BAP1 gene mutations in Egyptian patients with advanced sporadic malignant pleural mesothelioma (MPM): relation with clinical outcomes and survival.
Bahnasy AA; El-Din RS; Sabri NA; Abdel-Rahman CA; Bastawisy AE
Cancer Genet; 2018 Dec; 228-229():83-92. PubMed ID: 30553477
[TBL] [Abstract][Full Text] [Related]
26. Phase 2 study of sorafenib in malignant mesothelioma previously treated with platinum-containing chemotherapy.
Papa S; Popat S; Shah R; Prevost AT; Lal R; McLennan B; Cane P; Lang-Lazdunski L; Viney Z; Dunn JT; Barrington S; Landau D; Spicer J
J Thorac Oncol; 2013 Jun; 8(6):783-7. PubMed ID: 23571475
[TBL] [Abstract][Full Text] [Related]
27. Thoracic stop-flow perfusion in the treatment of refractory malignant pleural mesothelioma: a phase I-II evaluation/trial.
Guadagni S; Clementi M; Valenti M; Fiorentini G; Cantore M; Kanavos E; Amicucci G
In Vivo; 2006; 20(6A):715-8. PubMed ID: 17203752
[TBL] [Abstract][Full Text] [Related]
28. Oral cyclophosphamide and etoposide in treatment of malignant pleural mesothelioma.
Gunduz S; Mutlu H; Goksu SS; Arslan D; Tatli AM; Uysal M; Coskun HS; Bozcuk H; Ozdogan M; Savas B
Asian Pac J Cancer Prev; 2014; 15(20):8843-6. PubMed ID: 25374217
[TBL] [Abstract][Full Text] [Related]
29. Third-line chemotherapy with carboplatin, gemcitabine and liposomised doxorubicin for malignant pleural mesothelioma.
de Lima VA; Sørensen JB
Med Oncol; 2015 Feb; 32(2):458. PubMed ID: 25572813
[TBL] [Abstract][Full Text] [Related]
30. Multidisciplinary palliative treatment including isolated thoracic perfusion for progressive malignant pleural mesothelioma: a retrospective observational study.
Guadagni S; Masedu F; Zoras O; Zavattieri G; Aigner K; Guadagni V; Fumi L; Clementi M
J BUON; 2019; 24(3):1259-1267. PubMed ID: 31424688
[TBL] [Abstract][Full Text] [Related]
31. Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052).
O'Brien ME; Gaafar RM; Popat S; Grossi F; Price A; Talbot DC; Cufer T; Ottensmeier C; Danson S; Pallis A; Hasan B; Van Meerbeeck JP; Baas P
Eur J Cancer; 2013 Sep; 49(13):2815-22. PubMed ID: 23791541
[TBL] [Abstract][Full Text] [Related]
32. SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM).
Ou SH; Moon J; Garland LL; Mack PC; Testa JR; Tsao AS; Wozniak AJ; Gandara DR
J Thorac Oncol; 2015 Feb; 10(2):387-91. PubMed ID: 25611229
[TBL] [Abstract][Full Text] [Related]
33. Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey.
Zucali PA; Simonelli M; Michetti G; Tiseo M; Ceresoli GL; Collovà E; Follador A; Lo Dico M; Moretti A; De Vincenzo F; Lorenzi E; Perrino M; Giordano L; Farina G; Santoro A; Garassino M
Lung Cancer; 2012 Mar; 75(3):360-7. PubMed ID: 21937142
[TBL] [Abstract][Full Text] [Related]
34. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
Zalcman G; Mazieres J; Margery J; Greillier L; Audigier-Valette C; Moro-Sibilot D; Molinier O; Corre R; Monnet I; Gounant V; Rivière F; Janicot H; Gervais R; Locher C; Milleron B; Tran Q; Lebitasy MP; Morin F; Creveuil C; Parienti JJ; Scherpereel A;
Lancet; 2016 Apr; 387(10026):1405-1414. PubMed ID: 26719230
[TBL] [Abstract][Full Text] [Related]
35. Malignant pleural mesothelioma: an update on diagnosis and treatment options.
Kondola S; Manners D; Nowak AK
Ther Adv Respir Dis; 2016 Jun; 10(3):275-88. PubMed ID: 26873306
[TBL] [Abstract][Full Text] [Related]
36. A new prognostic index for overall survival in malignant pleural mesothelioma: the rPHS (regimen, PS, histology or stage) index.
Kataoka Y; Yamamoto Y; Otsuki T; Shinomiya M; Terada T; Fukuma S; Yamazaki S; Hirabayashi M; Nakano T; Fukuhara S
Jpn J Clin Oncol; 2015 Jun; 45(6):562-8. PubMed ID: 25838292
[TBL] [Abstract][Full Text] [Related]
37. Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma.
Krug LM; Wozniak AJ; Kindler HL; Feld R; Koczywas M; Morero JL; Rodriguez CP; Ross HJ; Bauman JE; Orlov SV; Ruckdeschel JC; Mita AC; Fein L; He X; Hall R; Kawabe T; Sharma S
Lung Cancer; 2014 Sep; 85(3):429-34. PubMed ID: 25047675
[TBL] [Abstract][Full Text] [Related]
38. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.
Calabrò L; Morra A; Fonsatti E; Cutaia O; Amato G; Giannarelli D; Di Giacomo AM; Danielli R; Altomonte M; Mutti L; Maio M
Lancet Oncol; 2013 Oct; 14(11):1104-1111. PubMed ID: 24035405
[TBL] [Abstract][Full Text] [Related]
39. Safety and efficacy of helical tomotherapy following lung-sparing surgery in locally advanced malignant pleural mesothelioma.
Layer JP; Fischer P; Dejonckheere CS; Sarria GR; Mispelbaum R; Hattenhauer T; Wiegreffe S; Glasmacher AR; Layer K; Nour Y; Caglayan L; Grau F; Müdder T; Köksal M; Scafa D; Giordano FA; Lopez-Pastorini A; Stoelben E; Schmeel LC; Leitzen C
Strahlenther Onkol; 2024 Jul; 200(7):605-613. PubMed ID: 37993554
[TBL] [Abstract][Full Text] [Related]
40. [Systemic Treatment of Malignant Pleural Mesothelioma].
Nakano T
Gan To Kagaku Ryoho; 2017 Dec; 44(13):2041-2047. PubMed ID: 29361614
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
